Abstract
Purpose: Inhibition of COX-2 enzymes is a frequently suggested mechanism for the beneficial effects of NSAIDs on carcinogenesis. The aim of this study was to explore the role of cumulative NSAID use on four common nonskin related cancers and modification by COX-2 G C genotype. Patients and methods: 7621 participants of The Rotterdam Study were included. In a mean follow up period of 10 years, 720 colorectal, lung, breast or prostate cancers occurred. Cumulative NSAID use was calculated per NSAID class. Individual associations of NSAID use and COX-2 G C genotype on cancer risk were explored with Cox proportional hazard models. Next, the association of NSAIDs and cancer stratified by COX-2 genotype was studied. Finally, the effect of combinations of NSAID use and COX-2 genotype on survival times was investigated. Conclusion: Our results confirm the protective effect of NSAID use on colorectal cancer. Individuals diagnosed with colorectal cancer who carry a COX-2 C allele and are on NSAIDs have an increased survival in comparison to non-users with the wild type .
Keywords: Anti-Inflammatory Agents, Non-Steroidal [MeSH], Cohort Study [MeSH], Cyclooxygenase 2 (inhibitors) [MeSH], Neoplasms [MeSH], Polymorphism, Single Nucleotide [MeSH]
Current Cancer Drug Targets
Title: Protective Effect of NSAIDs on Cancer and Influence of COX-2 C G Genotype
Volume: 8 Issue: 8
Author(s): C. Siemes, L. E. Visser, J. W.W. Coebergh, A. Hofman, A. G. Uitterlinden and B.H. Ch. Stricker
Affiliation:
Keywords: Anti-Inflammatory Agents, Non-Steroidal [MeSH], Cohort Study [MeSH], Cyclooxygenase 2 (inhibitors) [MeSH], Neoplasms [MeSH], Polymorphism, Single Nucleotide [MeSH]
Abstract: Purpose: Inhibition of COX-2 enzymes is a frequently suggested mechanism for the beneficial effects of NSAIDs on carcinogenesis. The aim of this study was to explore the role of cumulative NSAID use on four common nonskin related cancers and modification by COX-2 G C genotype. Patients and methods: 7621 participants of The Rotterdam Study were included. In a mean follow up period of 10 years, 720 colorectal, lung, breast or prostate cancers occurred. Cumulative NSAID use was calculated per NSAID class. Individual associations of NSAID use and COX-2 G C genotype on cancer risk were explored with Cox proportional hazard models. Next, the association of NSAIDs and cancer stratified by COX-2 genotype was studied. Finally, the effect of combinations of NSAID use and COX-2 genotype on survival times was investigated. Conclusion: Our results confirm the protective effect of NSAID use on colorectal cancer. Individuals diagnosed with colorectal cancer who carry a COX-2 C allele and are on NSAIDs have an increased survival in comparison to non-users with the wild type .
Export Options
About this article
Cite this article as:
Siemes C., Visser E. L., Coebergh W.W. J., Hofman A., Uitterlinden G. A. and Stricker Ch. B.H., Protective Effect of NSAIDs on Cancer and Influence of COX-2 C G Genotype, Current Cancer Drug Targets 2008; 8 (8) . https://dx.doi.org/10.2174/156800908786733414
DOI https://dx.doi.org/10.2174/156800908786733414 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design of Selectively Activated Anticancer Prodrugs: Elimination and Cyclization Strategies
Current Medicinal Chemistry - Anti-Cancer Agents Cyclotron Production of PET Radiometals in Liquid Targets: Aspects and Prospects
Current Radiopharmaceuticals Mechanisms of Action of Imidazoacridinone and Triazoloacridinone Derivatives in View of their Biological Activity
Current Pharmaceutical Analysis Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors
Current Pharmaceutical Design Neuroblastoma and Stem Cell Therapy: An Updated Review
CNS & Neurological Disorders - Drug Targets Aspirin: from a Historical Perspective
Recent Patents on Cardiovascular Drug Discovery Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets Nutrient-By-Genotype Interactions and Personalized Diet: What Can We Learn From Drosophila and Evolutionary Biology?
Current Pharmacogenomics and Personalized Medicine Pharmacogenetics of Cytochrome P450 (CYP) 1A2 and Variability in Psychotropic Drug Response
Current Psychiatry Reviews Current Gene Therapy Strategies for Colorectal Cancer
Current Genomics Gastrointestinal Stromal Tumors: A Paradigm for Therapeutic Options in Solid Organ Tumors
Mini-Reviews in Medicinal Chemistry Metastasis: Recent Discoveries and Novel Perioperative Treatment Strategies with Particular Interest in the Hemostatic Compound Desmopressin
Current Pharmaceutical Biotechnology Furanodienone: An Emerging Bioactive Furanosesquiterpenoid
Current Organic Chemistry Recent Advances in Epitope Design for Immunotherapy of Cancer
Recent Patents on Anti-Cancer Drug Discovery Calcium-related Neurotoxicity of Oxaliplatin: Understanding the Mechanisms to Drive Therapy
Current Medicinal Chemistry Targeting the Tumor Proteasome as a Mechanism to Control the Synthesis and Bioactivity of Matrix Macromolecules
Current Molecular Medicine Gene Expression Abnormalities in Thymoma
Current Pharmacogenomics Mesenchymal Stem Cells: Key Actors in Tumor Niche
Current Stem Cell Research & Therapy IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued)